CT-868
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Carmot Therapeutics, Inc · Phase 2 · Completed · Enrollment 103
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r | n/r |
| CT-868 1.75 mg | n/r | n/r | n/r | n/r | n/r |
| CT-868 4.0 mg | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.